In order to better understand the challenges to provision of optimal care to neuroendocrine tumor (NET) patients, today the International Neuroendocrine Cancer Alliance launches SCAN – a global survey designed to capture both NET patients’ and healthcare professionals’ perspectives.. Аs an umbrella organization of 26 NET patient advocacy and research groups across 6 continents, INCA works to fulfill the informational needs of patients, ensure access to the highest standards of care and facilitate patient involvement in research.

SCAN is an acronym standing for Survey of Challenges in Access to Diagnostics and Treatment for NET Patients. It aims to collect robust global data and answer key questions related to awareness and availability of NET diagnostics and treatments worldwide versus the out-of-pocket costs for those living with NETs.

The survey is available in 14 languages: Arabic, Bulgarian, Chinese, Dutch/Flemish, French, English, German, Hindi, Japanese, Italian, Portuguese, Russian, Spanish, and Swahili.

Under the motto We SCAN, the International Neuroendocrine Cancer Alliance invites NET patients and their carers, medical oncologists, endocrinologists, gastrointestinal specialists, pathologists, nuclear medicine specialists, surgeons, hematologists, pulmonologists, radiologists, psychologists, general practitioners and nurses to share their opinion. Mapping the access challenges worldwide from both the patients’ and healthcare professionals’ perspectives will help the NET community build a strong argument about global equity. The survey can be completed at from September 16 till October 31, 2019. SCAN does not collect any personal data and is completely anonymous.

Data from the survey would be initially disseminated around World NET Cancer Day, November 10th. SCAN results will be showcased at medical conferences, published in medical journals, presented at meetings with the decision-makers in the healthcare field to shine light on the gaps in access to early diagnosis, treatment and optimal care globally.

For more information on SCAN, visit . #wescan